Is Biogen Stock a Buy?
Investors who bought shares of Biogen (NASDAQ: BIIB) in 2010 or earlier and held onto them have plenty of reason to smile; Biogen has gained more than 390% since 2010. Last year, its portfolio of more than 10 drugs, including partnered therapies, generated $13.5 billion in total revenue.
Investors who are newer to the Biogen story, though, might not be as happy. The stock is down 40% from the high it reached in March 2015, and it finished last year 1.4% lower after the company scrapped development of its Alzheimer's drug aducanumab, but then reinstated the program.
Image source: Getty Images.
Source Fool.com
